This application aims to investigate the presence and the activation mechanisms of precursor cells in lung tissue of patients with pulmonary arterial hypertension (PAH), a group of deadly diseases without curative treatment options. It is increasingly acknowledged that the cells in the angioproliferative lesions are apoptosis-resistant, and recent years have generated substantial information about the contribution of bone marrow (BM)-derived precursor cells to vascular remodeling mainly in animal models, but it is unknown whether or not BM-derived and resident precursor cells contribute to angioobliterative PAH in human patients. The current literature also lacks a detailed understanding of the mechanisms of precursor cell activation in PAH. Preliminary data in our animal model of SU5416/chronic hypoxia (SuHX) indicates that precursor cells expressing various stem and progenitor cell markers accumulate in and around angioobliterative lesions and that some of these cells may be self-renewing stem cells. In human tissue of PAH patients, we have detected a similar distribution of cells staining positive for these stem and progenitor cell markers as in the SuHX model. This proposal is an extension of our animal work to detect stem and progenitor cell marker, activation/differentiation factors by immunofluorescence staining and confocal microscopy, as well as angiogenic and precursor activation potential of human PAH lung tissue and serum by in vitro angiogenesis assay and cell culture. Although animals models are important to investigate disease mechanisms and treatment strategies, it is necessary to examine human tissue specimens to increase the translational value of our animal data.

Public Health Relevance

Pulmonary Arterial Hypertension (PAH) is a crippling disease leading to early death of the patients and as current therapies do not target the abnormal growth of vascular cells obliterating pulmonary vessels, a curative treatment has not been found so far. Over the past years, evidence has been generated that cells with self-renewal or replacement features, so called precursor cells, may contribute to the changes in vascular architecture in human PAH, but the origin of these cells (bone marrow or lung) and their mechanism of action in the human lung tissue are incompletely understood. This application will investigate the presence of stem and progenitor cells more detailed in human PAH tissue samples and pay attention to activation mechanisms by histological and in vitro methods with the goal of finding novel targets to inhibit the abnormal cell growth in the lung vasculature and thereby increase survival of PAH patients.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Small Research Grants (R03)
Project #
1R03HL114816-01
Application #
8352565
Study Section
Special Emphasis Panel (ZHL1-CSR-Q (M2))
Program Officer
Moore, Timothy M
Project Start
2012-08-01
Project End
2014-06-30
Budget Start
2012-08-01
Budget End
2013-06-30
Support Year
1
Fiscal Year
2012
Total Cost
$74,750
Indirect Cost
$24,750
Name
Virginia Commonwealth University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
105300446
City
Richmond
State
VA
Country
United States
Zip Code
23298
Farkas, Daniela; Alhussaini, Aysar A; Kraskauskas, Donatas et al. (2014) Nuclear factor ?B inhibition reduces lung vascular lumen obliteration in severe pulmonary hypertension in rats. Am J Respir Cell Mol Biol 51:413-25
Farkas, Laszlo; Kolb, Martin (2013) Vascular repair and regeneration as a therapeutic target for pulmonary arterial hypertension. Respiration 85:355-64